COMMUNIQUÉS West-GlobeNewswire

SciSparc: Subsidiary NeuroThera Highlights Enhancement of U.S. Patent Portfolio Through Collaboration with Clearmind Covering LSD, Ketamine and Ibogaine Combinations
23/09/2026
The U.S. patent applications cover proprietary combinations of NeuroThera’s PEA technology with LSD, ketamine and ibogaine for potential therapeutic applications, including mental health disorders, such as depression [...]
Palisade Bio Expands Global Phase 2b ASCENTRA-UC Program with Health Canada CTA Clearance
23/09/2026
Canadian clearance supports site activation and enrollment in the global study of once-daily oral PALI-2108 Primary efficacy results from approximately 204 patients with moderately to severely active ulcerative colitis [...]
Cannabix’s BreathLogix Alcohol Screening Solution Enters U.S. Manufacturing Workplace Market with Deployment at Alabama Facility
23/09/2026
VANCOUVER, British Columbia, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTCID: BLOZF) (Frankfurt: 8CT) (the “Company” or “Cannabix”) developer of marijuana and alcohol breath testing [...]
Optimi Health Completes Psilocybin Production for Health Canada-Approved Phase 2 MDD Trial and Commercial TRD Supply
23/09/2026
One cGMP batch, manufactured in-house under Optimi's Health Canada Drug Establishment Licence, supplies both the Canadian trial and Australian clinics VANCOUVER, British Columbia, Sept. 23, 2026 (GLOBE NEWSWIRE) -- [...]
Pycnogenol® Offers Clinically Backed Cognitive Support Across Generations
23/09/2026
Research on French maritime pine bark extract spans children, students, working professionals and older adults looking to stay mentally sharp GENEVA, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Brain health is no longer a [...]
IRADIMED CORPORATION To Participate in the 5th Annual ROTH Healthcare Opportunities Conference
23/09/2026
ORLANDO, Fla., Sept. 23, 2026 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (“Iradimed”) (NASDAQ: IRMD), a leading provider of innovative magnetic resonance imaging (MRI) compatible medical devices, announced today that it [...]
Bionano Laboratories Announces Expansion of Diagnostic Testing Based on Optical Genome Mapping for Hematologic Malignancies
23/09/2026
SAN DIEGO, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Bionano Laboratories, a wholly-owned subsidiary of Bionano Genomics, Inc. (Nasdaq: BNGO) that offers CLIA-certified laboratory developed test (LDTs), today announced [...]
BioCardia Confirms Timing and Provides Update on FDA Helix Pre-Submission and PMDA CardiAMP HF Shonin Submission
23/09/2026
SUNNYVALE, Calif., Sept. 23, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today provided [...]
MAIA Biotechnology Expands Pivotal Phase 3 THIO-104 Non-Small Cell Lung Cancer Trial into Spain and Portugal
23/09/2026
THIO-104 advances toward key 2027 interim survival analysis CHICAGO, Sept. 23, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company [...]
NEXGEL Announces Dial-In Details for Investor Update Call
23/09/2026
LANGHORNE, Pa., Sept. 23, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a company with a patient centric medical technology sales and marketing team working closely with clinicians [...]
Cheryl Polmatier Joins U.S. Oral Surgery Management as SVP of Payer Relations
23/09/2026
IRVING, Texas, Sept. 23, 2026 (GLOBE NEWSWIRE) -- U.S. Oral Surgery Management ( USOSM ) – a management services organization that exclusively serves premier oral and maxillofacial surgeons – has named Cheryl Polmatier [...]
Coherus Oncology Retains Oppenheimer & Co. to Market Legacy BioSimilar Assets
23/09/2026
- Oppenheimer Initiates a Robust Process with Global Reach for the Benefit of Shareholders - REDWOOD CITY, Calif., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS) today announced that it has [...]
NexLife Includes a Licensed Doctor, a Nutrition Plan and Health Check-Ins After Treatment Starts in Every Compounded GLP-1 Subscription
23/09/2026
Every NexLife compounded GLP-1 subscription includes a doctor's review, a personalized nutrition plan and a 1:1 fitness coaching call alongside the medication. Ongoing care runs through Care 360, giving members 24/7 [...]
Lift Therapeutics Appoints Daniel Passeri as Chief Executive Officer
23/09/2026
Veteran biotechnology executive, Daniel Passeri brings more than three decades of experience in oncology and immunotherapy drug development - Interim CEO Dr. Bo Rode Hansen resumes role as member of the Board of [...]
ITM and Lumara Bio Announce Upcoming Dosimetry and Re-treatment Data Presentations on ¹⁷⁷Lu-edotreotide at ASTRO 2026
23/09/2026
Garching / Munich, September 23 , 2026 — ITM Isotope Technologies Munich SE (ITM) , a leading radiopharmaceutical biotech company, and Lumara Bio , a dedicated oncology therapeutics division of ITM, today announced that [...]
La rage chez les otaries à fourrure du Cap : ce que les nouvelles recherches sud-africaines pourraient signifier pour le Canada
23/09/2026
OTTAWA, Ontario, 23 sept. 2026 (GLOBE NEWSWIRE) -- L’Institut canadien de santé animale (ICSA) est fier de perpétuer sa tradition annuelle consistant à organiser un webinaire éducatif à l’occasion de la Journée mondiale [...]
Rabies in Cape Fur Seals: What New South African Research Could Mean for Canada
23/09/2026
OTTAWA, Ontario, Sept. 23, 2026 (GLOBE NEWSWIRE) -- The Canadian Animal Health Institute (CAHI) is proud to continue its annual tradition of hosting an educational webinar in recognition of World Rabies Day. This year’s [...]
ANI Pharmaceuticals Announces the FDA Approval of Everolimus Tablets for Oral Suspension
23/09/2026
PRINCETON, N.J., Sept. 23, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that it received final approval from the U.S. Food and Drug Administration (FDA) for its [...]
Oruka Therapeutics Announces Positive Week 28 Data for ORKA-001 from the Ongoing EVERLAST-A Trial Showing Deepening of Responses Without Additional Dosing
23/09/2026
PASI 100 increased to 71.4% and PASI 90 increased to 87.3%, despite no dosing after Week 4 Placebo crossover patients reached PASI 100 and PASI 90 rates similar to those initially dosed with ORKA-001 ORKA-001 maintained [...]

Pages